Skip to main content
Premium Trial:

Request an Annual Quote

HGS, Fifteen Years in Review

The Washington Post featured an article on Human Genome Sciences' epic battle to get a drug to market. The story follows a patient who receives an experimental drug for hepatitis in a time that, for HGS, represents "the clearing of its biggest hurdle to date: The Rockville company, now nearly 15 years old, has finally entered the last stage of testing for one of its drugs." (HGS expected to bring another drug, this one for lupus, to the same testing phase in a matter of days.)

The article also takes readers on a nostalgic stroll to the beginning of HGS, when founder William Haseltine seemed to investors and (some) pharmaceutical companies like a sure bet. Fifteen years later, those people are holding their breath and hoping that these drugs will turn out to be the wonder they've been awaiting.


The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.